000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type

Interventional

Phase

Phase 1 / Phase 2

Age range

15 years - 99 years

Sex eligible

All sexes

Healthy volunteers

Not accepted

Participants

96 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

Protocol # 000860

Background:

Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed.

Objective:

To see if a study drug (zotiraciclib) is effective in people with recurrent diffuse gliomas who have IDH1 or IDH2 mutations.

Eligibility:

People aged 15 years and older with diffuse gliomas that returned after treatment. They must also have mutations in the IDH1 or IDH2 genes.

Design:

Participants will be screened. They will have a physical exam with blood and urine tests. They will have tests of their heart function. They will have an MRI of their brain. A new biopsy may be needed if previous results are not available.

Zotiraciclib is a capsule taken by mouth with a glass of water. Participants will take the drug at home on days 1, 4, 8, 11, 15, and 18 of a 28-day cycle. They may also be given medications to prevent side effects of the study drug. The schedule for taking the study drug may vary for participants who will undergo surgery.

Participants will be given a medication diary for each cycle. They will write down the date and time of each dose of the study drug.

Participants will visit the clinic about once a month. They will have a physical exam, blood tests, and tests to evaluate their heart function. An MRI of the brain will be repeated every 8 weeks.

Participants may remain in the study for up to 18 cycles (1.5 years).

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

• INCLUSION CRITERIA:
• Participants must have diffuse glioma, WHO grades 2-4, histologically confirmed by certified neuropathologistI.
• IDH1 or IDH2 mutation status confirmed by TruSight(TM) Oncology 500 performed in LP, NCI or prior documentation of IDH1 or IDH2 mutation status
• Participants must have received prior treatment (e.g., radiation, conventional chemotherapy, or vorasidenib) prior to disease progression.
• Participants must have recurrent disease, proven histologically or by imaging studies
• Participants who have undergone prior surgical resection are eligible for enrollment to cohorts 1-4.
• Age \>15 years
• Karnofsky \>70%
• Participants must have adequate organ and marrow function as defined below:

• leukocytes \>=3,000/microliter
• absolute neutrophil count (ANC) \>=1,500/microliter
• platelets \>100,000/microliter
• total bilirubin \<=2x ULN (ULN 1.3 mg/dl) except for participants with Gilbert Syndrome
• AST \< 3x ULN (ULN 34U/L)
• ALT \< 3x ULN (ULN 55U/L)
• serum creatinine \< 1.5 mg/dL
• calculated creatinine clearance by CKD-EPI equation \> 60 cc/min
• Participants must have recovered from the adverse effects of prior therapy to grade 2 or less (per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0)
• Individuals of child-bearing potential (IOCBP) and men must agree to use highly effective contraception (hormonal, intrauterine device (IUD), abstinence, tube ligation, partner has had a previous vasectomy) at the study entry, for the duration of study treatment, and up to 3 months after the last dose of zotiraciclib
• Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 3 months after study treatment discontinuation
• Participants must be scheduled for brain tumor biopsy or surgical resection at NIH (Cohort 5 only)
• The ability of a participant, parent or legal guardian of minor participant to understand and the willingness to sign a written informed consent document. No Legally Authorized Representative can provide initial consent.

EXCLUSION CRITERIA:

• More than one disease relapse in those with initial diagnosis of WHO grade 3-4, or more than two disease relapses in those with initial diagnosis of WHO grade 2 for Phase II. For Phase I enrollment, there are no limits on the number of prior recurrences.
• Prior therapy with:

• any investigational agent (including IDH mutant inhibitor) and/or standard of care cytotoxic therapy within 28 days prior to treatment initiation
• vincristine within 14 days prior to treatment initiation
• nitrosoureas within 42 days prior to treatment initiation
• procarbazine within 21 days prior to treatment initiation
• non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, within 7 days prior to treatment initiation
• surgery within 14 days prior to treatment initiation
• radiation therapy within 30 days prior to treatment initiation
• bevacizumab for tumor treatment. Note: participants who received bevacizumab for symptom management, including but not limited to cerebral edema, or pseudo progression can be enrolled
• Prolonged QTc \>470ms as calculated by correction formula on screening electrocardiogram (ECG) (QTCf can be used; QTCb can be used for participants with sinus bradycardia)
• Prior invasive malignancies within the past 3 years prior to study treatment initiation (with the exception of non-melanoma skin cancers, carcinoma in situ of the cervix, melanoma in situ, or any localized cancer for whom the systemic standard of care therapy is not required)
• History of allergic reactions attributed to compounds of similar chemical composition to zotiraciclib, such as flavopiridol
• Pregnancy (confirmed with beta-HCG serum or urine pregnancy test performed at screening)
• Uncontrolled intercurrent illness or social situations that would limit compliance with study requirements
• Uncontrolled primary diabetes mellitus

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Not randomized

Masking

No masking

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Secondary measures

Research locations (2)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

2 locations

Study team and timeline

Lead sponsor

National Cancer Institute (NCI)

Study start

May 16, 2023 Actual

Primary completion

Aug 1, 2028 Estimated

Study completion

Aug 2, 2032 Estimated

First posted

Oct 20, 2022 Actual

Last updated

Nov 10, 2026 Actual

Official study contacts